TMO - Earnings call transcript Q2 2018 | Thermo Fisher Scientific Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2018 Second Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. Thank you. I would like to introduce our moderator for the call, Mr. Investor President, Vice Apicerno, Relations. Kenneth Mr. begin Apicerno call. you may the

Kenneth J. Apicerno

for today. morning and us you thank Good joining

call me and of Senior second the call archived Executive the Chief On on until with Officer. in is Officer; section and August our A Financial earnings Financial copy Presentations section and and quarter Chief being available President the webcast heading Stephen will our note XX, Results. of Investors Williamson, and the expectations Please Webcasts Vice under release the live and thermofisher.com of is President this Marc website be under Casper, our press is our future XXXX the XXXX. Investors website of heading

our we plans for remarks Securities important Safe which statements with Securities the including under Harbor results XX, available also a from and section our under So those Act provisions heading we March looking indicated constitute Safe Investors Commission before statement. differ Harbor report of of may materially XXXX. future the various Risk XX-Q company's expectations, factors about on website file under the these cover of that the and result company's the forward-looking ended prospects those discussed Filings. for caption of the and the is XXXX is by quarterly statements report on as forward Private begin, let Factors in purposes Form Exchange the in briefly may Reform make Various Litigation Actual me the SEC

subsequent of measures GAAP of if A estimates representing the and forward-looking and today. prepared expectations accounting financial be on XXXX specifically future, to on Also certain comparable GAAP the under heading Information. not principles should referring we'll accepted Investors do our GAAP. some release to non change. point to date we measures the in to Therefore during not to directly these our of or statements of the these the our looking you measures earnings even obligation available any financial second elect at any in as section as may While so disclaim call accordance reconciliation views statements we website our most update forward rely press Financial quarter also is generally with future in the

Marc. So I'll to with the over that, call turn now

Marc N. Casper

Thank for joining Ken. us for everyone. you morning Thanks call. QX our today Good

As you and terrific saw in in achieved revenue quarter. our excellent another earnings. delivered release, growth press we We

our markets. team to end Our well executed the capitalize strength of continued on

progress our products proposition. scale strategy We markets customer advancing continued key to emerging and customer launching growth unique great in by our new value leveraging make also that delivering address in needs

and very As we're for another the great quarter behind a we starting a on with our first competitive both I'll capitalize the in continue result excellent us, an overview year. financial successful half results. to of With our achieve to position cover position. strengthen an highlights

grew Our XX% $X.XX per share share in QX. adjusted earnings per to

to year-over-year increasing quarter $X.X was And income in QX billion. $X.XX billion. operating the revenue Our XX% also our in adjusted margin strong increased XX% was operating And adjusted very to XX.X%.

competitive a put benefiting us to and gain continue us clearly commitment strategy a to a performance position our momentum. our proven we're result the time allowed While of executed well favorable has now dynamics, is share that and end market primarily from over growth period our in long unique of

delivering in delivered by with our continue market. mid-single digits and in market. all to remained drive the healthcare, these businesses have biotech, color our unique in Now help innovation we of the saw grew broad-based businesses here and in our to Conditions we by with you end this let In ongoing and by on market. In and robust productivity. quarter we you with share little a proposition diagnostics end across end slice end serving me it value growth mid-teens QX this Starting whether customers strength markets gain or serving pharma strength them the our we with geography. customer performance across QX, strength set give

market in to the we we in see delivered an in the it and U.S. grew QX. in increase geographies mid-single was high-single-digits analytical strong the instrument funds good in in the Turning businesses. customer and our industrial We highlighted well digit and this applied, did continued government, Last, in by in growth quarter, of demand to flow in end all academic

on comment good quick geographic China We globe a in a our momentum and with strong the better the across perspective. from growth our XX% make continued end me our quarter. markets overall saw in than performance Let in conditions we

So growth our by global coupled QX. of the strong execution team competitive to excellent during conditions position strength led great market with our and

Now, let business our me strategy. make in some on of the growth remarks highlights context our

strategy our high impact of element innovative new products. one know, developing you is As

here we result success a the value creates morning. in We deep gain great of is had ongoing them. in industry-leading investment number we're ensure a QX of for markets them from research, a the customers R&D this work closely to way and I'll putting a in insights examples clinic for collaborate the and We few applied cover working most customers. our Our our that of to that

applications. the in during the structural Tribrid we Scientific leading applications our in much patient last developed This in productivity improve from our lab necessary Thermo mutations The assay It in we sequencing cancers food in young is a in GOLD of In last we and and Conference molecule U.S. ranging adult KRYPTOR UHMR next-gen Thermo [for] instrument while Precision center we care. to the Orbitrap we Oncomine that assay in here Specialty give metabolomic an platform. for. discovery ID-X a the to of that help promotes Mass range system Los process analysis. identifies Hospital collaboration technologies will pediatric an proteomic June Hybrid is that And quarter. Spectrometry customers launches to Diagnostics, the American (sic) at providing safety. business, And in First, in expand Q leading our indicate in advance specifically Angeles. is technologies Exactive streamline on characterization to access work the analysis global B.R.A.H.M.S. Children's offer and Center the small individualized drug to the creates patients. real combines system progress automated increasing China new KRYPTOR complements panel new Thermo with we Medicine in opened analyzer to year two make the Center launched immunoassay The including integrated Science number their workflow Society Quadruple Scientific in collaboration that instruments a biology comprehensive had of them faster opened known genomic, Europe. This quality blood comment Precision One that helps customers Medicine Scientific innovation samples protein

element is growth The our high leveraging markets. emerging strategy second of in growth our scale and

earlier, continued highlight China in these outstanding As QX. where geographies I mentioned we across was The strength saw we another quarter. delivered

with us scale customers growth tactical priorities country's earlier summit our Our is help and strategy organized of may opportunities advantage plan to and the leveraging up this global meet recall the the execution full us our This we enabling many plan. in from in depth leaders scientific great healthcare. sets of and government, the academia in year China in a that capabilities is have. those well with of take Precision very outlined objectives we year key five you unmatched of thought medicine Beijing to along one

infrastructure outcomes the that have another great of of build applications our an providing scale range is depth. in Technologies, One Analytical of multi-omics advantages a because industry-leading we're China example and the precision support This of in our for to of medicine. help now we is

our our Our good the prospects. created long-term for region a and feel advantage has expanding presence clearly us very we focus competitive on in about

our and our Now, always is relationships and to gain. strategy, which element it deepen to proposition. customer The share both want making This stronger I'll allows M&A. I the turn that to of is here customer value us we're drive through last key unique make point organically our complementary growth

Let me businesses to and of position value of the our executed couple to strengthen create how M&A more examples give drive growth. we our strategy you a for our customers

the of systems to of our to customers then, well agreement FEI electron of allow help Gatan, acquire part of these microscopy as for cameras improve couple company. microscopy Since capabilities these and business announced software know performed our years the a filters, acquisition Adding through of electron addition leading our about discoveries. recently electron ago. of performance us a you We their the accelerate to manufacturer will extremely First, business has microscopes.

to XXXX. expect complete of the We by the transaction end

At strengthen emerging implemented strong customer to in capacity business. is excellence our System leading customer through drive expanded and Technologies a investments our reagent offering operational accelerate Cytometer we've the in growth value proposition is XXXX. Today, you, We access margins the in our we've example launched great and how talked our scale of our strategy Another new the Life the our in on a a highlighted and to low-single-digits. relationships accounts remind to business Business program. clear leveraging had high-single-digits. while customer expand we about science with and seen the business accelerate that PPI markets, is that I the Fisher biosciences in successful strategy. business in that portfolio. the we've significantly was products haven't of fruits We through R&D further Scientific created combination in by this additional to that the corporate We number our the a this our Attune life industry Flow channel, like established creating consumables past. to time, of the our growing We enhancing while, and growing

this to in our microscopy new on acquisition the premier a of biosciences enhancing pipeline electron business. integration examples our slightly excited also will and to customers believe well. growth targets then another The on is leveraging is depth and the To We're investments value running new revenue our QX. adding our our on capabilities prospects performing and for we're further digital already over to and the have for update From business quick very scale development made meaningful synergy continually about capabilities synergy well and with long-term. very a give and brand. perspective, the make going growth business a synergy the one helping smoothly seeing impact strong the growth ahead our We commitment differentiate Patheon year stronger. Both of we're strong in strong reinforce you as this by web quarter Invitrogen

an I'll Before capital update revised on cover guidance, I give our you deployment.

and pipeline, of outlined beginning our the M&A from which As objectives acquisition, returning the a shareholders. to the were our at capital an a reminder, maintaining delevering of year, combination we Patheon active

So for the strategic and worth repurchased far acquisition $XXX you great returned Stephen made will dividends billion an details. buybacks of July. delevering bolt-ons in we've M&A give shares $XXX pending million stock the million of committed including Gatan perspective, this we've and through progress through that year and $XXX including in capital of million we've also From we $X

continue execute So customers our successfully create we to value deployment and for capital strategy to our shareholders.

Turning to our guidance.

over we're our and our the based strong both a As foreign raising release, guidance XXXX. on is growth $XX.XX operational our in result adjusted primarily for billion a XXXX. EPS This $XX.XX would partially you favorable exchange new guidance performance, revenue The to press for less to in offset year. by revenue saw XX% increase our raising billion of XX% to environment. range We're

In we we XX% now performance growth over per delivered lead guidance, expect our to will deliver adjusted adjusted the XXXX. $XX.XX XX% to $XX.XX between strong EPS EPS This and to in of terms share.

the CFO, of key our And I'll With growth to to of outstanding results summarize Stephen takeaways XXXX us very that in do hand the our our excellent strategy our to our half continue to our competitive up sets So to Williamson. teams executing now achieve an another strengthen Stephen? over QX, year. from job successful position. first call

Stephen Williamson

versus on conclude company, total updated good a quarter then earnings take our at with you through everyone. some level the second and color expectations four time overview of of call. our our morning, our guidance. performance business high framing segments, our I'll results Thanks, for Marc an provide XXXX the start QX our last I'll with of

acquisition, by QX continued line stronger quarter. of strong favorable and had adjusted than strong execution This at we'd the $X.XX Of press market XX% and You $X.XX below great midpoint saw quarter our continued was X% a earnings guidance. $X.XX strong share the we adjusted in assumed that organic from the was from with previous Patheon We the growth, very by per delivered growth EPS contributions driven more driven operational organic growth. $X.XX release FX in conditions. the and in by more

So another excellent quarter.

with on Let details per QX me earnings you give more Starting share. out. how played

XX% we up was XX% This and to EPS from $X.XX quarter grew adjusted last EPS QX $X.XX year. by the GAAP

components foreign the X% X% On line, year-over-year. exchange. XX% grew QX acquisitions growth organic and growth, of top XX% included our our benefit from The reported reported a revenue from revenue

growth at Looking by geography.

As globe in digits. across were strong mid-single the Europe QX. the America Marc markets grew mentioned, digits. our in North high-single grew

Pacific growth rest also low-teens. of grew in of in in low-teens the quarter with Asia grew including strong another world China, the – and the very

operating operating from XX% and basis QX Turning adjusted increased margin year. XX.X%, to points our last operational adjusted was XX performance. down income QX

dilutive operating effect and quarter in margins points our As lower income acquisition through to The total expectations. Patheon adjusted was the The QX. is operating company gross approximately line our than margins continue of margins scale the addition Patheon basis average. to will a adjusted to operating dilutive with be XX in reminder, the with margins

Foreign operating margin the exchange about to points contributed quarter. during basis XX

strategic quarter good volume was net unfavorable underlying by strong basis in the and productivity, expansion So and by operational and mix. acquisitions points at leverage FX, of partially of business driven XX our performance offset investments

to is was as which a X% these of in of was the basis basis manufacturing QX margin down year. dilutive total by versus Moving the XXX Strong due points in quarter SG&A at prior offset of XX.X% on at came XX versus revenue XXXX in QX Total X.X%. from Adjusted expected adjusted in of QX, of came percent points basis last of revenue, P&L. R&D and down acquisitions. gross more details was the than down the productivity revenue, to in the impact company XX expense our QX significant were acquisitions. year. points R&D Both XX.X% primarily

other QX Looking as at up million, $XX our results activities mainly from deployment driven the exchange. was incremental foreign Adjusted $XXX versus changes $XX and Net the non-operating million, a quarter our to is of QX million $X income result in of million related a line. below interest debt primarily expense was XXXX. in by favorable the expense year in last net income which XXXX capital

Our of primarily in of tax quarter Patheon. reform adjusted due versus XX.X% XX last and year was tax to the down impact addition rate the basis U.S. points the

slightly As last year-over-year. million, discrete higher expected, to tax diluted timing the quarter of adjusted planning tax due rate average was were QX than items. the shares XXX million up XX

QX, in cash continuing flow $XXX flow to free from and in returned XX% we to half ended early quarter cash $XXX growth. we cash completed $XXX the and year-to-date and first share $XX investments operations through and the of $X.X deducting Turning was with million in dividends Cash million buybacks. shareholders represents the of quarter. net We million was And year the expenditures cash million. after flow for billion sheet. the capital of free billion balance flow $X.X This

in year previous line for of million a complete for in is guidance. with XXXX. This $XXX $XXX We later our total expect to million the another

sequentially billion $X.X Our of the at total QX. QX debt $XX.X from end down was billion

basis leverage ratio points up on company end was total adjusted up ROIC EBITDA Our And last quarter. quarter performance, XX.X%, X.X my from the wrapping XX the debt total comments was times X.X of last at adjusted times down our quarter. to from

was operating of very XX.X%, the Instruments had segments. partially very XX% across revenue saw So strategic we segment, points Starting growth in organic the a the Instruments in Life now Analytical and businesses microscopy. performance operating Segment good genetic reported growth across XX% the chromo this next-gen organic growth In and strong XX% In I'll quarter, favorable Solutions, income color biosciences drove revenue quarter, reported offset revenue XXX operating QX business and good businesses year-over-year. very adjusted impact This In the Life we adjusted of increased from you In strategic and of we and mass in income Sciences with XX% quarter, in spec good QX all and was our increased in some X%. basis we segment by basis quarter, strong sciences. margin points grew leverage, all margin chemical adjusted on was Solutions productivity X%. increased XXX analysis, up Analytical was QX volume pull-through, sequencing, electron bioproduction, QX operating adjusted segment; provide up saw Sciences and XX.X%, was investments. FX. in revenue our In and productivity the clinical the partially by our offset the volume very investments. year-over-year. saw in growth four

operating Specialty QX adjusted and was operating diagnostics saw had was prior impact we X%. and the year. In this QX, businesses favorable good Turning mix. organic Segment. and of also diagnostics healthcare and QX In income channel. clinical growth We from flat revenue strong market leverage, in quarter, X% the in offset Diagnostics transplant grew the saw total FX to a in investments compared and revenue Adjusted volume was X% our increased to the strategic margin XX.X%, business by and growth

income market accretive In saw the to slightly margin was from the acquisitions XX% good safety down increased year. were research segment the segment operating the volume points Products we reported Finally, Adjusted strong includes Laboratory in growth Services trials the business X%. segment, saw and acquisition, all In QX our revenue which across increased Organic revenue quarter, the Patheon our we clinical basis leverage. Segment, adjusted and channel. was growth the XX%. XX.X%, in prior led logistics businesses operating and and XX margins and quarter, by in the

offset strategic was investments. business more and by mix this than However,

updated guidance. year XXXX move full I'll now So to our on

revenue both per and the share earnings press release, guidance. saw You we're adjusted in our raising

The I'll increase raising million the of revenue tightening of our midpoint the you details. consists and by by through $XX the guidance me to with Let revenue. start million. the walk range million We're $XX midpoint elements. three $XX

million our be outcome organic $XXX likely for outlook organic increase in most year growth XXXX to now year. for X%. the We First, growth see the full

Second, a now in FX the at $XX million rates, midpoint the expect the year of million. from given for less a reflecting which And Patheon. increase acquisitions, environment full movement revenue the performance favorable exchange reduces we strong third, $XXX by continued

of gross by reduction impact of expected $X.XX increasing the two to $X.XX a guidance Turning per operational these to year; favorable headwinds share. EPS increase changes than This reflecting performance our FX; interest adjusted prior offset costs. due midpoint from of expected following reflects in $X.XX the reduction earnings the increase guidance; second half stronger a tariffs as adjusted our the well as to We're the less due to the $X.XX lower by due are and more $X.XX.

expected to So growth to now revenue benefit of $XX.XX FX updated to to a this growth of A now $XX.XX of a be our which per earnings or of is few adjusted for in And gross XXXX XX% of range exchange or to have a XXXX represents XXXX to our share guidance. in X% sum the this X% our revenue is with midpoint to of to impact guidance billion, approximately plan the a for We now billion guidance X%. is XXXX. guidance. operational growth estimate offset updated second to that and adjusted XX% and for other tariffs the earnings XX% revenue is million now assumed We now expect the $XX share. represent about of EPS is these our details $X.XX on reflected XXXX million XXXX. assuming $XXX year versus per up, or range of versus $XX.XX. be X.X%. revised on FX is offsets to tailwind foreign This $X.XX behind and acquisitions the We're half adjusted reported XX% the contribute $XX.XX benefit of tailwind the We XXXX $XX.XX company

there's net on impact So XXXX. tariffs no to

for margins, operating adjusted points basis deliver we to of points XX continue terms of basis to expansion the to year. XX expect In

to the impact change the no this represents of guidance. from of points points XX Patheon, basis XX Excluding expansion, previous basis

benefits income over in in guidance expense We interest net We're of to due expense now expect net $XXX improvement to just to million slight range be assuming that realized $XX QX. be $XXX of the million, to and non-operating other to prior a million. our income FX

authorization and income in XX% million for We rate continue complete in expect to we've deployment And later in $XXX recently recent is million buybacks line $XXX the we our the strategy year, with the $XXX replenish guidance. mentioned $XXX fully tax another a in level in my XXXX. at total of as an expect consistent completed the Later deplete of with buybacks for This to to the Analyst year expect in we the adjusted authorization. earlier long-term The previous a year. million May. of Meeting current remarks, outlined million will of share capital at our

return We shares year range assume of divestitures. approximately we'll will in to from capital average our million. any million And does million acquisitions not the continue through future be guidance no that shareholders XXX to $XXX of diluted to dividends, guidance. change include or previous the expect XXX We full

to will the for comments guidance. from of about cash for it on $XXX doesn't the pending rest previous Gatan. previous flow, impact approximately change consistent finally, we're And, of with of a full the guidance. million billion And million, capital We're expenditures include year. net So $XXX year, no from $X.X acquisition be phasing for assuming free couple the expecting any

than in revenue to QX just We expect prior QX. growth Then of be comparison QX. strength EPS phasing, expect QX the of adjusted year QX higher over XX% the organic terms than to rate to be higher in we in due

quarter position call that, to delivered in we a deliver point and the QX we're at another turn successful year. I'll over great to halfway back the summary, very Ken. With in in So, excellent a

Kenneth J. Apicerno

questions. Operator, Stephen. take to we're ready Thanks,

Operator

you. Thank

ISI. first Our from line question comes with the Muken Ross Evercore of

open. is line Your

Ross Muken

Good gentlemen. morning, Congrats. Hi.

Marc N. Casper

Ross. you, Thank

Ross Muken

result is So maybe Marc. let's the mean, China, just spectacular. start I on

guess, to peer there, going the sort quarter. it XX%. dynamics the at of sort the the I be And continued that's underlying of group unique of probably general, you as share you for some sort dominance best but in You're look implies the exposure, of and like. have face the It's in in in north of the end and made you sort basic raw various of industry of some the cadence the there on maybe are the about tariffs given materials about markets uncertainties? uncertainty. rest point are the some of year, and Some sort obviously, sort How of or feeling the the – you for of incremental on worried of the side.

Marc N. Casper

for the questions. thanks Ross,

So and is with let the the first the talk across I'll half. the growth going well China over about bit little me The first was little then extremely back and tariffs. about a the talk there a and performance looking about beginning to performing in at and quarter various sets. business just XX% broad-based of in strong the Very I later forward year. customer the XX% for quarter momentum,

about bullish is is outlook. very base of the things the customer their One

of sort that you things some things of trade base. amongst that papers in the really the see not the customer dialog is So, about and a

So unique and the and for the do of across strong. markets because and labs country. depth of we position We it base very business-as-usual the really the is our scale scientific are really have there capabilities competitive customer have a

tariffs. market our long targeting us is in really primarily from comment Our that Really, A perspective. does, and of presence that the helps the industry. on our from really and tariffs R&D quick seeing outside benefit teams really a you're thinks things scale performance

affecting little the customer outlook. not really exposure. very It's there's So

pricing cost sourcing and Stephen that are our is in tariffs As And enacted. have to half we chain said, gross going year our of and the to on operationally there the of be about that supply second those a fully and enacted from actions. offset $X.XX impact through actions scheduled

we the is it, to on anticipate don't any extra through articulate just it's everybody we at will call and because want but navigate the color we So that and looking new world gave that issues. something in

Ross Muken

just Great. And maybe Stephen. for one

heard core make better see. confirm, of of of, if it want case? Did of sort is I just growth QX normally dynamics. the that the to be given because earnings one, that I for I like sure called think to half, obviously in magnitude greater in implying out, you may to XQ? in see the want just And right. going growth something EPS than seems margin but in to that that's XX% the I XQ XQ, better some what I above be second cadence seems terms then that's you – want secondarily, we say terms

Stephen Williamson

So you correct, got Ross. numbers the

I think, year. the the that in call period on the One bringing Patheon a and dynamics the such couple the our in that out. are back down of profitable QX the last in to And one-time headwind is, numbers is bonus impact stub company's tax that's of cost into time of two this margins in second Puerto QX QX. amount from by not the significant strong lot hurricane side in really impact to the expansion, to year the get to equivalent in up Rico. which for factors running. we a things factor that have expended and QX large then QX, of was in Patheon what you've did Site year, payment a And going in and QX are QX of last a and non-repeat, reform we seen things, the scale driven margin to repeat we'll some of happened site related

tailwind for gives strong in you drive you margin that dynamic XX% that QX, difference. to So fact gives the

Ross Muken

Thank Great. so you much.

Marc N. Casper

Thanks, Ross.

Operator

Lynch. comes Merrill question America with de next Derik of Bank from line the Bruin of Our

is line Your open.

Derik de Bruin

morning. good Hi,

Marc N. Casper

Derik. morning, Good

Derik de Bruin

one I focused so on question and Hey, more then sort one question picture big just one. – like of a have

when Dionex the of sort big molecule and I like sort small think and better talk the the I'll and an required quality start look the player you you curious some have been do – with how it's an markets about market in how QA/QC (XX:XX) those of other the focused biologics? and market assurance of are not to just compare does of opportunity – given bit small question sort Can how drug there you molecules historically not to profitability these first, in little do you're yet quality in the positioned the opportunities technologies for like a has that like a Thermo each gain acquisition. at share. biologics control, And was

Marc N. Casper

Derik. question. Yeah, the for Thanks

terms In in the of in attribute that spectrometry players mass with how a we've with thought multi adopted. this one method in considered partnered of has we the QA/QC really being the biotech biologics, on number applications are evolved that of leaders

the a So and bigger biologics the our our well perspective a very spectrometry bigger of mass and profitability QA/QC based as positioned, platform, of the quite total strength Orbitrap is franchise we're industry portion on strong. from biotech pharma become of and

So perspective, are in really sustained a great drive from growth. position to we that

Derik de Bruin

Okay. And big the follow up on then just picture. more question

You've really now of strong had spectacularly quarters three growth.

– revenue that growth looking This concerns is I about comps quarters. last there X%, think sort potentially difficult begs of question about going I at X%, anything the look forward curious could but X% able X% it's concerns up. are your you in next obviously into you're confidence the of more horizon end what three it's your to target? just And sort sort guess X% the give on bit upper year, little a guess seeing like did think core it. in are too sort I'm the of markets? to organic I pop know, in about growth maintain of of as what forward look the and your guidance you your end to I early I being

Marc N. Casper

question. Great Yeah, Derik.

driving are, customers very we really more and is our by such it's the our positive they're environment same competitive business to us. look position So if at valued being at I point, where that

I second our maintain X% year versus in the going for look quarters seeing it's the we have year. the the the guidance rate increase and a that great market a as that growth three year. the our we're in industry. the seen that previous If spectacular outlook, differential assumes versus for half to You're the have obviously the conditions the guidance small in at last have others there's When to organic then growth for at

positive. XXXX guidance our in here now XXXX. very half full storm on it give are January, we'll looks any see and excited I don't sitting least think about our clouds So outlook we very all late at you year horizon right but Obviously, second the we about as outlook,

Derik de Bruin

Great. in Thanks. back queue. I'll get the

Operator

comes question the with next of JPMorgan. Our line Peterson Tycho from

Your line is open.

Tycho W. Peterson

comments. I'm curious on Hey, fits much I know Marc, this it you quarter. the How with overlap customer here? overall? maybe minute cross-sell opportunity to wondering there prepared But you FEI thanks. can your in is how a if What comment in Gatan. Great just mentioned is?

Marc N. Casper

Yeah.

about provides in is be the we're to is filters, When It even get get doing Gatan. the customers what a value that strategic microscopy about the looking and investments systems of excited electron the really their cameras to to from very fit to components with benefits here you software. Gatan more industry we able business. we're really good and think want the help So including

the you the So the it very for make adoption business know, goal easier is of microscopy technology here and to growing as is well. electron

the close we'll of So when attractive that transaction we're very into trying this well. transaction to compelling all as the It's But extremely capability. financials year out details of an financially end then. and the also market the we'll well we are the the lay through expand economics as and towards get the

Tycho W. Peterson

Okay. as we obviously biopharma, And think numbers, up then about great putting mid-teens. you're up

You issues. budget share. yesterday flush We about peer talk gaining have commented did a on

So suffice also in on you quarter? say, trends see necessarily saw there? didn't And is and can it the of any that you the comment you to bioprocess

Marc N. Casper

Yeah.

and the chromo trials in mass from range mid-teens base of our our feel We about pharma channel. all customer was safety spec, excellent, that. clinical and good biotech, research strength that logistic businesses and across growth that and saw serve bioproduction So

the board, instruments, instruments, So we consumables, across mass a spectrometry very production, good chromatography so from quarter. strength saw

we positioned drive really unique that how to and innovation are our proposition we and think productivity. uniquely I have reflects customers' it value customer the

Tycho W. Peterson

one for then one quick And Okay. Stephen. last

Just on Or increasing how CapEx Will should Patheon around going that that CapEx? kind we Patheon. of assume think is Should run about rate? the forward? we steady-state be current this

Stephen Williamson

Yeah.

CapEx full built I think year. you'll see range. the within It's into this for number the

Tycho W. Peterson

Okay.

Stephen Williamson

Thanks, Tycho.

Tycho W. Peterson

you. Thank

Operator

with Meehan Barclays. question of from next Our comes Jack line the

is line open. Your

Jack Meehan

morning. good and Thanks,

Marc N. Casper

Good morning, Jack.

Stephen Williamson

morning. Good

Jack Meehan

obviously, share get thoughts you growth your some and on hoping good was just this in resonating business. in gain more logistics in very and So elaborate on be quarter. I'd could a the particular, the curious little the just services of you top highlight the is think to that, bit biopharma and commentary I areas

Marc N. Casper

Yeah.

say, a strong it's disaggregate I company it gains, quite and the when the share very competitors a well the But the you can fared of terms you broad-based. in in look mean, as field. Jack the company, at whole So well, as I very about had think quarter. pieces, we the versus narrower

has So our well. performed business

Thermo there reagents doing us continue a Clinical customers mass to move logic businesses how chromatography business, acquired safety as in-house strong Scientific. very really Fisher the of business quarter, market Those our like our nice where were strong. benefit spectrometry of what the clinical a gain because channel. large business, to of with of more trials and logistics, Patheon the even We're customers we and research share three Some highlights seeing all our and of we and the actually trials activity why quarter bioscience understand saw trusted is it. in think partner more they're more the I

Jack Meehan

as on posted Great. Specialty this of to follow was growth a just one want I dig And performance. X%. That that consistent up. then the only Diagnostics in quarter the

So growth just would any great? get Cascadion on be updates side you're the innovation about to talk on and the what up doing

Marc N. Casper

Sure.

quarter Chemistry other business to in is we'll the it next clinical Clinical we and across Outside of of starting strength commercialization NGS good instruments quarter outside instrument serving Association and base, in ramp Cascadion, to broad-based serving at or number be this a healthcare XXXX transplant a also CE-IVD got showcasing So start really a contributor (sic) customer the in our the year. the channel. week we which the we whether Chicago, and good had in it market Not Conference, along and happening business clearance launching [for] American with diagnostics, in portfolio. market. meaningful the Jack, diagnostics are Expect of our U.S. was that healthcare our clinical but diagnostics performance diagnostics are healthcare, that

in diagnostics and mid-single going good the digit and healthcare business of things lots on So a with very growth. quarter solid

Jack Meehan

Great.

seeing then. guys. Looking forward to it Thanks

Marc N. Casper

you. Thank

Operator

comes & line with Our of from the next Doug Company. Cowen Schenkel question

is line open. Your

Doug Schenkel

Hey, good morning, guys.

Marc N. Casper

morning, Doug. Good

Doug Schenkel

to just on Patheon. start Maybe

really effort the were to the some sustainability? it's still the then P&L, down quarter customers done to and terms that we think I'm with in moving or of too if any the I'm the appear curious early strength revenue just Patheon much better cross-selling needle. of of key move to in improvement both for And You than Thermo if curious expected margins. how is to the about should and to biopharmaceutical related margin drivers larger have what

Marc N. Casper

really the and over combination well is the extraordinarily time. is going feedback Doug, have the Yeah. leveraging just the and customer integration positive and trust relationships that also about the two built companies

been it's very positive. So

cadence revenue because In now. synergies, and the we pipeline a lot terms from the clearly XX interest of But show today revenue the can some win a business seeing are of momentum months wins. of up of in

So it but the prospects it affect does doesn't affect of short long the business. the term term growth

the Some wins cycle trials the in a much are is of clinical showing up business shorter which business.

that's positive. clearly So

business be I raise that two outlook quarters. good to our of able to that's the last going how been great in very feel about So and for it's each

So performing you to...? Stephen, well. want

Stephen Williamson

then PPI printing a Business driving across on operational growth the our margin synergies. and The very it's the very are System standpoint, of an of across a getting that's teams decent of good that just good make margin to synergies engaged the you across key sites of at and impact one kind the a using there. combination sites higher Patheon's And progress we're level and I'd granular a was there remind from business. traction at the Yeah, key level

Doug Schenkel

discussions Okay. That's back and I few really this you that's an a topic address helpful. want second one give go morning. for opportunity guess in my to guidance coming up to to And thing I just of our

core to monstrous of necks guidance just want seem beat. in materially. By conservatism just make there's all the targets sure you growth is none put want change and suggest of that magnitude that the for not second just is first It a to million seeing shouldn't to function issues, core any missing like close by pretty $XXX I I full you this quarter half. didn't increased the implies spite half something us year the fact second of You largely of sure revenue make this which here. that out anything extension, doesn't really revenue up are sure that but stick you're your that

Marc N. Casper

is the Doug. they be in the truly conditions. it had a market the strong now raise obviously the Yeah, If continue were conditions first a bit spectacular a for and that on a indicating organically, will we're there's that trajectory. a market very outlook the question. change half. QX good year. seeing little QX nothing that have half, Right in way We It's first We did specifically based

and feel about good on going every are of opportunity. maximizing guidance, the to but the I our focus So teams prudence obviously performance on capitalizing

this put we don't guidance we So any at close see always, to think the to expectations. year exceed And issues, point. as or we've able but be appropriate I want meet and

Doug Schenkel

helpful. Okay. you. Very Thank

Operator

comes Our Stanley. Beuchaw Steve of the question with from next line Morgan

Your line is open.

Steve Beuchaw

your if we've flagged then as something first and that But about particularly for important for all as and Good of little NIH you a now there bit. I an morning lot just as out the academic time. you was the Hi. Historically, wonder channel thought us lately thanks China a of positive. positive could the being guidelines barometer strong. and Europe coming a actually that's well are quarter unpack

for if little you could a on So unpack regional bit basis. academic wonder us a

Marc N. Casper

Yeah.

QX. growth, very future bodes and $XXX NIH's on which cryo-electron strong May excited to the the in based announcement the demand. average we microscopy well flowing company Steve, for by with research strength board. allocate well it's with just So, really for funds Starting good U.S., million quarter were the high-single-digit across performance. were below in Geographic NIH

So that what effect, the in on it's no obviously, $XXX quarter. had for million But target was very encouraging. XXXX,

was Horizon program Europe, very with announced. the that positive to Turning

decade. of the institutions across which is XXXX environment the program, next continent They to – closer because what to be. end billion the commitment announced is $XXX helps funding year Horizon which research So the seven academic the going to to really program advance we're funding getting of like know in a is

had focused very with their had to big some UK they their of for commitment ministers a make initiatives Brexit industry prior And life really in about number maintain has preparing heritage research sure to meetings So Europe. and sciences well. government a was their have in talk that as that the commitment

to looks China in see Europe So you continues obviously U.S. good. results. strong be and looks good. that the

we're in environment longer-term well globe. So of as across outlook what now as terms seeing very encouraging the right the

Steve Beuchaw

about the might performance across It relative And your just talk your could you is category follow-up Thanks out One then very, and very of like that. we question the I category. as about sounds zoom items. on if But for Okay. the a look to housekeeping funnel. Doug's thinking evolving just about Thanks so little And Patheon, about thinking? how much. to AI that bit CROs now impact on the CMOs, little the wonder you a growth feel franchise environment broader couple at across good on be color the services deal. is Does relative on trials, than and it organically then and broader pharma space thought you it time maybe like be good, the there any really helpful. does seem the your to FEI, forward better would of

Marc N. Casper

Sure.

well. last been years that are the acquisitions couple have over performing the integrated So extraordinarily

services our pro as pharma had have basis half. year a the prior been in would first on low-double-digit forma Patheon, we meaning Patheon growth the owned if of business in terms In

a and So execution very good and it's very, of very strong well. market performance as a good reflection

with company of electron electron had Electron the would X% company quarter a with average. microscopy good microscopy. microscopy, or similar have to terms of grown a contribution without as growth we In obviously, the rates,

Steve Beuchaw

again. Thanks

Operator

next with Our Donnelly the line from comes Patrick Sachs. of question Goldman

Your is line open.

Patrick Donnelly

quarter? can the to on the and I've be through hear perspective pharma outlook here. the data some particularly U.S. side. talk Marc, in the just just It would Thanks. performance you helpful seen Great. your points mixed in

Marc N. Casper

there's It's the in in growth digit good, Academic pockets and mid-single quarter. of U. we see was weakness any U.S. had good the in conditions. the good really didn't funding We S. dramatic

is the be strong to years, spot the of to number In nice last fact mid-single really a perspective. digit relative from growth actually domestic

didn't meaningful weakness the anything we So, really side. see on

Patrick Donnelly

feeling Can first maybe just given then growth, high going there? what about pretty still performed in on healthy. points just coming industrial than macro that color single provide you lighter the on applied out in are a bit are markets maybe here, the And digits data environment quarter, forward you well mid-single some little Okay. various but how some

Marc N. Casper

Yeah.

Analytical had segment, analysis in factors business applied. strong in of had would particular. quarter, and in mass in those driving nice comparisons Instruments still that spec, chemical obviously be and some Our in microscopy growth. the chrom growth some We in industrial the challenging had mid-single electron growth But the digit

Patrick Donnelly

franchise. forward, one markets execute let to to in on time question Maybe CDMO, CRO I being? just you on you the general see was any the prefer there just for just last would of market. or you as you I the if one could side. you attractive? know to the franchise going pipeline the adding touched, Patheon Can quarter last kind particularly talk during it FEI Thoughts sneak the adding Gatan M&A Obviously, your did deal through

Marc N. Casper

Yeah.

to M&A really have disciplined that use and we We're as our going and active transactions, do. very And pipeline. the M&A a we to have one the while across performance, we look And differentiated selection pipeline have So what at very from be a right? things we active about process very has think of our criteria is businesses. We financially. the firepower, so to in terms able we of a be execute many on management things selective have of we we lot ability a both

as do for position shareholder So creating the to as pipeline value. right and our we'll strengthening competitive transactions well progress continue that

Patrick Donnelly

you. Thank Great.

Operator

of Our next from with question Dan comes Arias the Citigroup. line

open. is line Your

Daniel Arias

you. to Thank Marc, the... Good morning, guys.

Marc N. Casper

Good morning, Dan.

Daniel Arias

Morning.

made already. of Obviously, couple headed of you terms historically you've the been top are where the in line. times been point that's a only guys Just organic

or categories when about sprinkling certain product you are evenly I'm the maybe call would incremental I being think the into So for bid or business, back the out whether you earmarked to being you're pretty it dollars more that just business? that say, investment across put you'd curious guess are areas

Marc N. Casper

a where bolster year. area highlighted, of business momentum an Web we and there, of on strategy those spectrometry, to would but of fully growth high-single obviously business. company acquisition of would the microscopy because transformed putting money electron every years now a biosciences, sprinkle them, We're in market areas really disciplined the than an and in a There levels to we Gatan an and mass digit, very to benefits like position. digit, sustainably low-single even our example. we right want that an our want it of that run don't increasing chromatography increased therefore were a lot and shows the would we we the example. further we thought in it's of had digit to a move, are there, In outlook strong that areas to and it good that's the we've very, sustain because that a good are conditions so number M&A invest in be we more very our few Taking the where we capitalize be example. digital, another our and an No, a capabilities mid-single faction given area the be area bright we work been investments I at outlook. the obviously Yeah. increased day say a of evenly investments that better for It's momentum bit just there I have we've execution investment businesses and an have rates just would

you're new it launches, whether in the cytometry, in flow product it seeing cell in You're it's biology. seeing

on our that we market. as competitive in well seeing in position the we're have as So to we're momentum specific investing the areas capitalize

Daniel Arias

for I Super. if one maybe Ken risk sneak more the could here, of Stephen. Okay. at crossing And in

whether there's about so forward? next opportunity going when particular you're at think level, call, or and the thinking curious, a you high year more margin a there's investment Just segment that over, just mix

Stephen Williamson

think over years. leverage you volume it played clearly, really the businesses. last the When The higher out about comes through couple of how Yeah. margin in, strong

Analytical shown have pull-through on the volume Life great Instruments Sciences So Solutions, organic growth.

a company. lot margin the where really So of you'll that's expansion see of the

Daniel Arias

Thank you guys. Okay.

Operator

question comes & line of next Brandon Our Couillard from Jefferies Company. the with

is open. line Your

Brandon Couillard

Good Thanks. Most morning. of...

Marc N. Casper

Hi, Brandon.

Brandon Couillard

having addressed be two speak the imply raised could one to year And just quarters context if curious already, free the of it the would In been in seems outlook ...my you row in only cash to X% about for you a questions guidance the flow full half. remains growth have now, second Stephen. which but unchanged?

just of half first timing some that the and conservatism or year? So second between is

Stephen Williamson

free the timing. last Yeah. think, it's cash in years cash Look $X.X flow flow as it's and average yes, of It's growth we gone years terms free a strong to We going as on year, up an and I combined, really the year. growth higher can. the range very in work XX% two of QX around hard we're to two billion had now at so deliver the for per much

Brandon Couillard

thanks. good, Very

Kenneth J. Apicerno

We for more. have one time

Operator

comes of Steve question with Cleveland Research. the line next Our Willoughby from

Your line is open.

Steve Barr Willoughby

year. I Patheon, as of for Good couple you digit it believe mentioned quick I the morning. you relates guys. first far in to A low-double growing things it's guess so this

year? segment. – that color I also half back market in the expecting to $X.XX guys. sort gains tariffs as or of it it strong that's implemented (sic) into out know does then you which Just How just in just the but share obviously been expect proposed, you're the growth to was versus finally, far? the enters account implemented just have an a calculation of then wondering the secondly, But that on number more not level a increase recently any guess Thanks organic if offset. of similar there? overall wondering, end much the you much that that tariffs, for or that X% I calling [LP&S] the you're And LPS growth relates very is so have of called as $XX out been in tariffs so take that the And growth, million

Marc N. Casper

some some. of I cover think it do I'll So Stephen and will

in So a the business our into strong growth flow haven't quarter. our in strong grew and of not in the the and Services very Patheon very We terms the growth Segment, as had channel clinical because reminder, logistics trials we anniversaried Lab Products numbers in the the transaction. does performance

drivers there. the were those So big

Stephen Williamson

Yeah.

couple rec true the will that comps in hitting side, QX when So think a us deferred about ahead rev pro forma. revenue the you that the model, QX. business deal we'd hit running so on we've in Patheon of growth in Underlying the and of underlying some is got be

in – total So be – and significant to beginning company expect then it's not of tariffs the in to piece a be second the QX, year to And we contributor really basically enacted it's what's half growth. of is or in baked we mid been the QX. going enacted QX assuming what

Marc N. Casper

Thank you, Steve.

Steve Barr Willoughby

Thank Okay. you.

Marc N. Casper

So the We're call. in ongoing XXXX. year. to pleased next achieve me excellent thank great obviously your of you look of for a Scientific. up the And to of deliver to position We a end updating We're support let half the very Fisher wrap an as first the successful quarter. you forward Thermo at always,

Thermo Fisher Scientific (TMO) 25 Jul 182018 Q2 Earnings call transcript